Aclaris Therapeutics Company Profile (NASDAQ:ACRS)

About Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics logoAclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company's drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACRS
  • CUSIP: N/A
  • Web: www.aclaristx.com
Capitalization:
  • Market Cap: $667.34 million
  • Outstanding Shares: 26,736,000
Average Prices:
  • 50 Day Moving Avg: $27.65
  • 200 Day Moving Avg: $27.92
  • 52 Week Range: $19.75 - $33.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.28
  • P/E Growth: -0.13
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.29 per share
  • Price / Book: 3.97
Profitability:
  • EBIDTA: ($49,560,000.00)
  • Return on Equity: -34.24%
  • Return on Assets: -32.76%
Debt:
  • Current Ratio: 21.02%
  • Quick Ratio: 21.02%
Misc:
  • Average Volume: 298,542 shs.
  • Beta: 2.25
  • Short Ratio: 17.74
 

Frequently Asked Questions for Aclaris Therapeutics (NASDAQ:ACRS)

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.68) by $0.12. View Aclaris Therapeutics' Earnings History.

When will Aclaris Therapeutics make its next earnings announcement?

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Aclaris Therapeutics.

Where is Aclaris Therapeutics' stock going? Where will Aclaris Therapeutics' stock price be in 2017?

5 equities research analysts have issued 12-month target prices for Aclaris Therapeutics' stock. Their predictions range from $34.00 to $50.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $40.00 in the next twelve months. View Analyst Ratings for Aclaris Therapeutics.

What are analysts saying about Aclaris Therapeutics stock?

Here are some recent quotes from research analysts about Aclaris Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (5/12/2017)
  • 2. Jefferies Group LLC analysts commented, "ACRS reported a narrower Q4 loss of $11.5M (vs $14.5M JEF) due to lower than projected R&D spend post the SK Ph3 trials. Attention now turns to three new clinical trials (A-101 Phase 2b in common warts and two JAK Ph 2s in alopecia areata) as we wait for an FDA decision on A-101 in SKs in early '18. We continue to forecast peak sales approaching $500M for the drug/device combo and think ACRS fits our M&A thesis." (3/16/2017)
  • 3. Guggenheim analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities." (3/15/2017)

Who are some of Aclaris Therapeutics' key competitors?

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the folowing people:

  • Stephen A. Tullman, Chairman of the Board
  • Neal Walker, President, Chief Executive Officer, Director
  • Frank Ruffo CPA, Chief Financial Officer, Secretary
  • Christopher Powala, Chief Operating Officer
  • Stuart D. Shanler M.D., Chief Scientific Officer
  • Kamil Ali-Jackson J.D., Chief Legal Officer
  • Richard A. Bierly, Independent Director
  • William D. Humphries, Independent Director
  • Anand Mehra M.D., Independent Director
  • Andrew Kenneth William Powell, Independent Director

Who owns Aclaris Therapeutics stock?

Aclaris Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (10.69%), Franklin Resources Inc. (7.31%), FMR LLC (7.09%), Sofinnova Management VIII L.L.C. (5.76%), Eagle Asset Management Inc. (5.08%) and Westfield Capital Management Co. LP (4.67%). Company insiders that own Aclaris Therapeutics stock include Albert Cha, Anand Mehra, Andrew N Schiff, Fmr Llc, Kamil Ali-Jackson, Ra Capital Management, Llc, Sofinnova Venture Partners Vii, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Aclaris Therapeutics.

Who sold Aclaris Therapeutics stock? Who is selling Aclaris Therapeutics stock?

Aclaris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, PointState Capital LP, Parametric Portfolio Associates LLC, Citadel Advisors LLC, Capital Impact Advisors LLC, Caxton Corp, Russell Investments Group Ltd. and Rothschild Asset Management Inc.. Company insiders that have sold Aclaris Therapeutics stock in the last year include Anand Mehra, Kamil Ali-Jackson, Ra Capital Management, Llc and Ventures Fund Vii LP Vivo. View Insider Buying and Selling for Aclaris Therapeutics.

Who bought Aclaris Therapeutics stock? Who is buying Aclaris Therapeutics stock?

Aclaris Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Franklin Resources Inc., Westfield Capital Management Co. LP, FMR LLC, Nexthera Capital LP, Marshall Wace North America L.P., State Street Corp and UBS Asset Management Americas Inc.. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Albert Cha, Andrew N Schiff, Fmr Llc, Ra Capital Management, Llc, Sofinnova Venture Partners Vii and Vivo Ventures Vii, Llc. View Insider Buying and Selling for Aclaris Therapeutics.

How do I buy Aclaris Therapeutics stock?

Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aclaris Therapeutics' stock price today?

One share of Aclaris Therapeutics stock can currently be purchased for approximately $24.96.


MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  138
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aclaris Therapeutics (NASDAQ:ACRS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $40.00 (60.26% upside)

Analysts' Ratings History for Aclaris Therapeutics (NASDAQ:ACRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Cantor FitzgeraldSet Price TargetBuy$50.00LowView Rating Details
7/31/2017Jefferies Group LLCReiterated RatingBuy$36.00HighView Rating Details
7/4/2017GuggenheimReiterated RatingBuy$40.00LowView Rating Details
11/29/2016Leerink SwannInitiated CoverageOutperformN/AView Rating Details
9/30/2016JMP SecuritiesInitiated CoverageOutperform$34.00N/AView Rating Details
3/16/2016Citigroup Inc.Lower Price TargetBuy$34.00 -> $29.00N/AView Rating Details
11/2/2015William BlairInitiated CoverageOutperform$30.00N/AView Rating Details
(Data available from 8/21/2015 forward)

Earnings

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)
Earnings by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Earnings History by Quarter for Aclaris Therapeutics (NASDAQ ACRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.86)N/AView Earnings Details
8/8/2017Q2 2017($0.68)($0.56)ViewListenView Earnings Details
5/9/2017Q1 2017($0.54)($0.48)ViewListenView Earnings Details
3/15/2017Q4 2016($0.59)($0.49)ViewN/AView Earnings Details
11/3/2016Q3($0.68)($0.50)ViewListenView Earnings Details
8/11/2016Q2($0.61)($0.62)ViewListenView Earnings Details
5/11/2016Q1($0.50)($0.65)ViewListenView Earnings Details
3/23/2016Q4($0.40)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aclaris Therapeutics (NASDAQ:ACRS)
2017 EPS Consensus Estimate: ($3.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.61)($0.45)($0.54)
Q2 20173($0.71)($0.64)($0.68)
Q3 20173($0.95)($0.84)($0.89)
Q4 20173($1.28)($1.00)($1.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aclaris Therapeutics (NASDAQ:ACRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Ownership Percentage: 16.30%
Institutional Ownership Percentage: 88.71%
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Andrew N SchiffDirectorBuy108,601$23.02$2,499,995.02View SEC Filing  
3/2/2017Ventures Fund Vii L.P. VivoMajor ShareholderSell425,000$30.82$13,098,500.00View SEC Filing  
1/10/2017Anand MehraDirectorSell750,000$28.25$21,187,500.00View SEC Filing  
11/18/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell907,828$23.03$20,907,278.84View SEC Filing  
10/26/2016Kamil Ali-JacksonInsiderSell3,912$21.83$85,398.96View SEC Filing  
9/28/2016Kamil Ali-JacksonInsiderSell1,841$24.66$45,399.06View SEC Filing  
9/16/2016Ra Capital Management, LlcMajor ShareholderSell525,550$24.19$12,713,054.50View SEC Filing  
8/26/2016Kamil Ali-JacksonInsiderSell3,738$20.35$76,068.30View SEC Filing  
2/23/2016Ra Capital Management, LlcMajor ShareholderBuy39,726$17.15$681,300.90View SEC Filing  
1/20/2016Ra Capital Management, LlcMajor ShareholderBuy7,803$19.87$155,045.61View SEC Filing  
1/13/2016Ra Capital Management, LlcMajor ShareholderBuy15,637$19.10$298,666.70View SEC Filing  
10/29/2015Ra Capital Management, LlcMajor ShareholderBuy244,200$14.00$3,418,800.00View SEC Filing  
10/22/2015Ra Capital Management, LlcMajor ShareholderBuy5,410$14.03$75,902.30View SEC Filing  
10/21/2015Ra Capital Management, LlcMajor ShareholderBuy34,999$14.89$521,135.11View SEC Filing  
10/14/2015Ra Capital Management, LlcMajor ShareholderBuy42,813$14.06$601,950.78View SEC Filing  
10/13/2015Albert ChaDirectorBuy454,545$11.00$4,999,995.00View SEC Filing  
10/13/2015Fmr LlcInsiderBuy335,455$11.00$3,690,005.00View SEC Filing  
10/13/2015Sofinnova Venture Partners ViiMajor ShareholderBuy409,090$11.00$4,499,990.00View SEC Filing  
10/8/2015Ra Capital Management, LlcMajor ShareholderBuy2,237,130$10.86$24,295,231.80View SEC Filing  
10/7/2015Vivo Ventures Vii, LlcMajor ShareholderBuy13,352$11.00$146,872.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aclaris Therapeutics (NASDAQ:ACRS)
Latest Headlines for Aclaris Therapeutics (NASDAQ:ACRS)
Source:
DateHeadline
americanbankingnews.com logoAclaris Therapeutics, Inc. (ACRS) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - August 20 at 9:28 PM
americanbankingnews.com logoAclaris Therapeutics, Inc. (ACRS) Director Andrew N. Schiff Acquires 108,601 Shares
www.americanbankingnews.com - August 16 at 7:39 PM
streetinsider.com logoAclaris Therapeutics (ACRS) Prices 3.26M Share Offering at $23.02/Sh
www.streetinsider.com - August 11 at 8:53 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Lifted by William Blair
www.americanbankingnews.com - August 11 at 10:45 AM
americanbankingnews.com logoResearch Analysts Set Expectations for Aclaris Therapeutics, Inc.'s Q3 2017 Earnings (ACRS)
www.americanbankingnews.com - August 11 at 10:14 AM
americanbankingnews.com logoQ3 2017 Earnings Estimate for Aclaris Therapeutics, Inc. Issued By Leerink Swann (ACRS)
www.americanbankingnews.com - August 11 at 10:14 AM
americanbankingnews.com logoFY2021 EPS Estimates for Aclaris Therapeutics, Inc. (ACRS) Reduced by Leerink Swann
www.americanbankingnews.com - August 10 at 2:20 PM
americanbankingnews.com logoWilliam Blair Weighs in on Aclaris Therapeutics, Inc.'s FY2020 Earnings (NASDAQ:ACRS)
www.americanbankingnews.com - August 10 at 1:52 PM
americanbankingnews.com logo Brokerages Expect Aclaris Therapeutics, Inc. (ACRS) to Post -$0.91 EPS
www.americanbankingnews.com - August 10 at 12:30 PM
finance.yahoo.com logoAclaris Announces Proposed Public Offering of Common Stock
finance.yahoo.com - August 9 at 8:44 PM
americanbankingnews.com logoAclaris Therapeutics, Inc. (ACRS) Issues Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - August 9 at 4:34 PM
finance.yahoo.com logoAclaris Announces Appointment of Andrew Schiff to Board of Directors
finance.yahoo.com - August 9 at 3:43 PM
americanbankingnews.com logoAclaris Therapeutics, Inc. (ACRS) Given a $50.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - August 9 at 1:32 PM
finance.yahoo.com logoEdited Transcript of ACRS earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 9 at 1:30 AM
bizjournals.com logoHouston VC-funded startup acquired in deal valued at $100 million
www.bizjournals.com - August 8 at 8:28 PM
streetinsider.com logoAclaris Therapeutics (ACRS) Acquires Confluence Life Sciences for $10M Cash, 350K Shares
www.streetinsider.com - August 8 at 8:28 PM
finance.yahoo.com logo[$$] Aclaris Therapeutics Buys Confluence Life Sciences in $100 Million Deal
finance.yahoo.com - August 8 at 8:28 PM
finance.yahoo.com logoAclaris Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 3:25 PM
finance.yahoo.com logoAclaris reports 2Q loss
finance.yahoo.com - August 8 at 3:25 PM
feeds.benzinga.com logoAclaris Therapeutics Acquires Confluence Life Sciences, Inc.
feeds.benzinga.com - August 8 at 8:07 AM
finance.yahoo.com logoAclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis
finance.yahoo.com - August 3 at 3:56 PM
finance.yahoo.com logoAclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata
finance.yahoo.com - August 2 at 3:23 PM
americanbankingnews.com logoAclaris Therapeutics, Inc. (NASDAQ:ACRS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:10 AM
finance.yahoo.com logoAclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - August 1 at 3:47 PM
finance.yahoo.com logoUPDATE - Aclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - August 1 at 3:47 PM
americanbankingnews.com logoAnalyzing Aeglea BioTherapeutics (AGLE) and Aclaris Therapeutics (ACRS)
www.americanbankingnews.com - August 1 at 12:14 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Aclaris Therapeutics, Inc. (ACRS)
www.americanbankingnews.com - July 31 at 7:20 PM
americanbankingnews.com logoAclaris Therapeutics, Inc. (ACRS) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 28 at 4:39 PM
americanbankingnews.com logo-$0.68 EPS Expected for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) This Quarter
www.americanbankingnews.com - July 21 at 7:36 AM
seekingalpha.com logoAclaris: Bright Future Ahead With Dermatology And Alopecia Treatments
seekingalpha.com - July 20 at 8:46 PM
americanbankingnews.com logoCantor Fitzgerald Comments on Aclaris Therapeutics, Inc.'s FY2017 Earnings (NASDAQ:ACRS)
www.americanbankingnews.com - July 17 at 10:22 AM
americanbankingnews.com logoAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 3 at 4:58 PM
streetinsider.com logoAclaris Therapeutics (ACRS) Commences Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
www.streetinsider.com - June 29 at 3:41 PM
finance.yahoo.com logoAclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
finance.yahoo.com - June 29 at 3:41 PM
americanbankingnews.com logoAclaris Therapeutics, Inc. (ACRS) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - June 28 at 11:28 AM
americanbankingnews.com logoZacks: Analysts Expect Aclaris Therapeutics, Inc. (ACRS) to Post -$0.68 EPS
www.americanbankingnews.com - June 27 at 9:04 AM
americanbankingnews.com logoAclaris Therapeutics, Inc. (ACRS) Receives New Coverage from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 16 at 10:06 AM
americanbankingnews.com logoAclaris Therapeutics, Inc. (ACRS) Upgraded at ValuEngine
www.americanbankingnews.com - June 15 at 9:26 PM
streetinsider.com logoAclaris Therapeutics (ACRS) Granted New U.S. Patent for A-101 Topical Solutions
www.streetinsider.com - June 13 at 3:18 PM
finance.yahoo.com logoAclaris Therapeutics Announces Issuance of New U.S. Patent For A-101 Topical Solutions
finance.yahoo.com - June 13 at 8:09 AM
americanbankingnews.com logoHead-To-Head Comparison: Aclaris Therapeutics (ACRS) vs. Paratek Pharmaceuticals (PRTK)
www.americanbankingnews.com - June 7 at 10:18 AM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - June 6 at 10:26 PM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - June 6 at 5:06 PM
americanbankingnews.com logo-$0.68 EPS Expected for Aclaris Therapeutics Inc (ACRS) This Quarter
www.americanbankingnews.com - June 1 at 9:14 AM
americanbankingnews.com logoAclaris Therapeutics Inc (ACRS) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 27 at 10:56 AM
americanbankingnews.com logoZacks Investment Research Lowers Aclaris Therapeutics Inc (ACRS) to Sell
www.americanbankingnews.com - May 12 at 4:40 PM
americanbankingnews.com logoJefferies Group Weighs in on Aclaris Therapeutics Inc's Q2 2017 Earnings (ACRS)
www.americanbankingnews.com - May 12 at 10:58 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Aclaris Therapeutics Inc (ACRS) Reduced by Leerink Swann
www.americanbankingnews.com - May 12 at 10:58 AM
americanbankingnews.com logoAclaris Therapeutics Inc to Post Q2 2017 Earnings of ($0.70) Per Share, William Blair Forecasts (ACRS)
www.americanbankingnews.com - May 12 at 10:42 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for Aclaris Therapeutics Inc's FY2021 Earnings (ACRS)
www.americanbankingnews.com - May 11 at 3:58 PM

Social

Chart

Aclaris Therapeutics (ACRS) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by MarketBeat.com Staff